$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

$avdl Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000101247724000012 Filed on May 08, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$41.50M	$27.18M	$0.00
YoY Change	2674.33%
Cost Of Revenue	$2.788M	$1.522M	$0.00
YoY Change	7644.44%
Gross Profit	$38.72M	$25.66M	$0.00
YoY Change	2551.78%
Gross Profit Margin	93.28%	94.4%
Selling, General & Admin	$47.41M	$48.62M	$24.47M
YoY Change	1.34%	98.72%	13.09%
% of Gross Profit	122.45%	189.52%
Research & Development	$4.051M	$3.068M	$3.830M
YoY Change	-4.07%	-19.9%	-45.22%
% of Gross Profit	10.46%	11.96%
Depreciation & Amortization	$437.0K	$541.0K	$588.0K
YoY Change	-27.29%	-7.99%	127.03%
% of Gross Profit	1.13%	2.11%
Operating Expenses	$51.46M	$51.69M	$28.30M
YoY Change	0.89%	82.67%	-1.15%
Operating Profit	-$12.74M	-$26.04M	-$28.30M
YoY Change	-74.28%	-8.0%	-1.15%
Interest Expense	-$2.716M	-$2.592M	-$3.259M
YoY Change	18.34%	-20.47%	61.58%
% of Operating Profit
Other Income/Expense, Net	$1.126M	$1.378M	$193.0K
YoY Change	80.74%	613.99%	-285.58%
Pretax Income	-$14.33M	-$27.25M	-$31.36M
YoY Change	-77.73%	-13.12%	2.01%
Income Tax	-$509.0K	$93.00K	-$580.0K
% Of Pretax Income
Net Earnings	-$13.82M	-$27.34M	-$30.78M
YoY Change	-78.55%	-11.18%	16.5%
Net Earnings / Revenue	-33.3%	-100.6%
Basic Earnings Per Share	-$0.14	-$0.30	-$0.48
Diluted Earnings Per Share	-$0.14	-$0.30	-$0.48
COMMON SHARES
Basic Shares Outstanding	96.12M shares	90.58M shares	64.48M shares
Diluted Shares Outstanding	96.15M shares	91.69M shares	63.89M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$71.38M	$88.79M	$100.9M
YoY Change	-55.53%	-12.02%	-18.27%
Cash & Equivalents	$28.85M	$35.79M	$83.39M
Short-Term Investments	$42.54M	$53.00M	$17.53M
Other Short-Term Assets	$672.0K	$3.320M	$542.0K
YoY Change	-89.6%	512.55%	247.44%
Inventory	$13.31M	$11.93M
Prepaid Expenses	$6.109M	$8.013M	$5.384M
Receivables	$33.38M	$22.69M	$269.0K
Other Receivables	$927.0K	$1.293M	$2.352M
Total Short-Term Assets	$125.8M	$136.0M	$109.5M
YoY Change	-26.54%	24.27%	-31.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$484.0K	$526.0K	$782.0K
YoY Change	-75.18%	-32.74%	191.79%
Goodwill	$16.84M	$16.84M	$16.84M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$12.02M	$11.77M	$10.93M
YoY Change	13.99%	7.66%	-72.42%
Total Long-Term Assets	$31.74M	$31.86M	$31.27M
YoY Change	6.71%	1.9%	-48.22%
TOTAL ASSETS
Total Short-Term Assets	$125.8M	$136.0M	$109.5M
Total Long-Term Assets	$31.74M	$31.86M	$31.27M
Total Assets	$157.5M	$167.9M	$140.7M
YoY Change	-21.62%	19.3%	-36.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.794M	$18.96M	$10.02M
YoY Change	-16.9%	89.17%	65.72%
Accrued Expenses	$33.71M	$27.64M	$7.683M
YoY Change	81.34%	259.78%	-18.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$20.52M
YoY Change			-21.65%
Total Short-Term Liabilities	$44.61M	$47.81M	$79.36M
YoY Change	-13.38%	-39.76%	80.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$93.14M
YoY Change		-100.0%	-20.07%
Other Long-Term Liabilities	$5.819M	$5.925M	$5.767M
YoY Change	-7.37%	2.74%	49.91%
Total Long-Term Liabilities	$5.819M	$5.925M	$98.91M
YoY Change	-7.37%	-94.01%	-17.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.61M	$47.81M	$79.36M
Total Long-Term Liabilities	$5.819M	$5.925M	$98.91M
Total Liabilities	$87.23M	$89.52M	$178.9M
YoY Change	50.96%	-49.97%	7.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$786.7M	-$772.8M	-$616.0M
YoY Change	15.61%	25.46%	29.91%
Common Stock	$881.2M	$875.0M	$603.9M
YoY Change	3.72%	44.9%	8.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$70.29M	$78.38M	-$38.17M
YoY Change
Total Liabilities & Shareholders Equity	$157.5M	$167.9M	$140.7M
YoY Change	-21.62%	19.3%	-36.35%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$13.82M	-$27.34M	-$30.78M
YoY Change	-78.55%	-11.18%	16.5%
Depreciation, Depletion And Amortization	$437.0K	$541.0K	$588.0K
YoY Change	-27.29%	-7.99%	127.03%
Cash From Operating Activities	-$18.19M	-$29.70M	-$30.23M
YoY Change	-43.21%	-1.75%	-11.2%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$10.55M	$21.39M	$5.066M
YoY Change	-111.36%	322.17%	-88.01%
Cash From Investing Activities	$10.55M	$21.39M	$5.066M
YoY Change	-111.36%	322.17%	-88.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	723.0K	$13.19M	$34.44M
YoY Change	-99.21%	-61.7%	1614.39%
NET CHANGE
Cash From Operating Activities	-18.19M	-$29.70M	-$30.23M
Cash From Investing Activities	10.55M	$21.39M	$5.066M
Cash From Financing Activities	723.0K	$13.19M	$34.44M
Net Change In Cash	-6.913M	$4.627M	$9.410M
YoY Change	-79.29%	-50.83%	-7.43%
FREE CASH FLOW
Cash From Operating Activities	-$18.19M	-$29.70M	-$30.23M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	1322000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11333000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5286000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	136035000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	134202000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	526000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	585000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2374000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2591000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	16836000	usd
CY2024Q1	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	360000	usd
CY2023Q4	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	332000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11768000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10152000	usd
CY2024Q1	us-gaap	Assets Assets	167899000	usd
CY2023Q4	us-gaap	Assets Assets	164698000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	5194000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5194000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89825000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89825000	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30784000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	588000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1873000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6093000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29704000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1522000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	25656000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	0	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3068000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3830000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48623000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24468000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36855000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	51691000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	28298000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-26035000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28298000	usd
CY2024Q1	us-gaap	Investment Income Net InvestmentIncomeNet	1378000	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	193000	usd
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2592000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	3259000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27249000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31364000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	93000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-580000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-27342000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30784000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91693000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63886000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91693000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63886000	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-27342000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30784000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-236000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	175000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-353000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	140000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-589000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	315000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27931000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30469000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35794000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31167000	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	52995000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	73944000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22692000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12103000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	11928000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	10380000	usd
CY2024Q1	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	1293000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	16836000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	953000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	934000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	18961000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11433000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27642000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24227000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	252000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	261000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	47808000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1449000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1690000	usd
CY2024Q1	avdl	Royalty Financing Liability Noncurrent RoyaltyFinancingLiabilityNoncurrent	34333000	usd
CY2023Q4	avdl	Royalty Financing Liability Noncurrent RoyaltyFinancingLiabilityNoncurrent	32760000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5925000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5654000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	89515000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	76959000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	52000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96097000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96097000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	960000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	898000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	874018000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	855452000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-772838000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-745496000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23756000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23167000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	78384000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	87739000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	167899000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	164698000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	87739000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-27342000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-589000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9250000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3356000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	584000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5389000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	78384000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-21145000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30784000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	315000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11913000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	16000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	29000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1522000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-38166000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-27342000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	541000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5389000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1522000	usd
CY2024Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-719000	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-1000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10589000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1260000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4131000	usd
CY2024Q1	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	17000	usd
CY2023Q1	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7528000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	468000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3415000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	348000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	557000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	116000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30233000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	119066000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	15295000	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	97679000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	10229000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21387000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5066000	usd
CY2024Q1	avdl	Proceeds Received In Advance Of Share Issuance ProceedsReceivedInAdvanceOfShareIssuance	0	usd
CY2023Q1	avdl	Proceeds Received In Advance Of Share Issuance ProceedsReceivedInAdvanceOfShareIssuance	40000000	usd
CY2024Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	usd
CY2023Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	17500000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9250000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11913000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3940000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	29000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13190000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34442000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-246000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4627000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9410000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31167000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73981000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35794000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83391000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	730000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	3050000	usd
CY2023Q2	avdl	Orphan Drug Exclusivity Term OrphanDrugExclusivityTerm	P7Y
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified within the notes to the unaudited condensed consolidated financial statements to condense line items of the same nature to conform with the current year presentation.</span></div>
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	52394000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	601000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	52995000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	72990000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	954000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	73944000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	398000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	1000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	61000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	52995000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	0	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	52995000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2024Q1	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	3368000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	5291000	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1359000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2037000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7201000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3052000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	11928000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	10380000	usd
CY2023Q1	avdl	Royalty Financing Proceeds Maximum RoyaltyFinancingProceedsMaximum	75000000	usd
CY2023Q1	avdl	Royalty Financing Quarterly Net Revenue Target RoyaltyFinancingQuarterlyNetRevenueTarget	25000000	usd
CY2023Q1	avdl	Royalty Financing Quarterly Royalty Payment Percentage RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage	0.0375
CY2023Q1	avdl	Royalty Financing Proceeds Maximum RoyaltyFinancingProceedsMaximum	75000000	usd
CY2023Q1	avdl	Royalty Financing Proceeds Maximum RoyaltyFinancingProceedsMaximum	75000000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	93000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-580000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.018
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8013000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4373000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	3320000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	913000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11333000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5286000	usd
CY2024Q1	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	11575000	usd
CY2023Q4	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	9905000	usd
CY2024Q1	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	193000	usd
CY2023Q4	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	247000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11768000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10152000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	15594000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	11961000	usd
CY2024Q1	avdl	Remaining Performance Obligation Reserve Current RemainingPerformanceObligationReserveCurrent	5712000	usd
CY2023Q4	avdl	Remaining Performance Obligation Reserve Current RemainingPerformanceObligationReserveCurrent	4044000	usd
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5317000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7492000	usd
CY2024Q1	avdl	Royalty Financing Liability Current RoyaltyFinancingLiabilityCurrent	1019000	usd
CY2023Q4	avdl	Royalty Financing Liability Current RoyaltyFinancingLiabilityCurrent	730000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27642000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24227000	usd
CY2024Q1	avdl	Tax Liabilities And Other Noncurrent Liabilities TaxLiabilitiesAndOtherNoncurrentLiabilities	5498000	usd
CY2023Q4	avdl	Tax Liabilities And Other Noncurrent Liabilities TaxLiabilitiesAndOtherNoncurrentLiabilities	5407000	usd
CY2024Q1	us-gaap	Guaranty Liabilities GuarantyLiabilities	427000	usd
CY2023Q4	us-gaap	Guaranty Liabilities GuarantyLiabilities	247000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5925000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5654000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-27342000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30784000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91693000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63886000	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91693000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63886000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	867000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12463000	shares
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001012477-24-000012-index-headers.html	Edgar Link	pending
0001012477-24-000012-index.html	Edgar Link	pending
0001012477-24-000012.txt	Edgar Link	pending
0001012477-24-000012-xbrl.zip	Edgar Link	pending
avdl-20240331.htm	Edgar Link	pending
avdl-20240331.xsd	Edgar Link	pending
exhibit311q12024.htm	Edgar Link	pending
exhibit312q12024.htm	Edgar Link	pending
exhibit321q12024.htm	Edgar Link	pending
exhibit322q12024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
avdl-20240331_def.xml	Edgar Link	unprocessable
avdl-20240331_lab.xml	Edgar Link	unprocessable
avdl-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
avdl-20240331_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
avdl-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

2024 Q2 Form 10-Q Financial Statement

#000101247724000012 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL AVADEL PHARMACEUTICALS PLC Stock $avdl

2024 Q2 Form 10-Q Financial Statement

#000101247724000012 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl